Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma.

@article{Miyahara2014EfficacyOS,
  title={Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma.},
  author={Koji Miyahara and Kazuhiro Nouso and Yuki Morimoto and Yasuto Takeuchi and Hiroaki Hagihara and Kenji Kuwaki and Hideki Onishi and Fusao Ikeda and Yasuhiro Miyake and Shinichiro Nakamura and Hidenori Shiraha and Akinobu Takaki and Shouta Iwadou and Yoshiyuki Kobayashi and Koichi Takaguchi and Yoshitaka Takuma and Hiroyuki Takabatake and Kohsaku Sakaguchi and Kazuhide Yamamoto},
  journal={Hepatology research : the official journal of the Japan Society of Hepatology},
  year={2014},
  volume={44 3},
  pages={296-301}
}
AIM We investigated whether continuous sorafenib administration keeps suppressing the growth of hepatocellular carcinoma (HCC) after first progressive disease (PD), and whether it prolongs patients' survival. METHODS The size of metastatic lesions was measured in 36 patients with advanced HCC treated with sorafenib. The tumor growth rates before and after radiological PD as well as survival were compared between the patients who continued (n = 23) and stopped (n = 13) sorafenib at first… CONTINUE READING
Highly Cited
This paper has 18 citations. REVIEW CITATIONS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 15 references

Similar Papers

Loading similar papers…